Patents by Inventor James Spoonamore

James Spoonamore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082316
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: August 9, 2023
    Publication date: March 14, 2024
    Inventors: Kristin ADOLFSEN, Per GREISEN, Isolde CALLIHAN, Adam LAWRENCE, James SPOONAMORE, Jay KONIECZKA
  • Publication number: 20240009291
    Abstract: The present invention is related to compositions and methods that reduce methane production in ruminant populations.
    Type: Application
    Filed: July 11, 2023
    Publication date: January 11, 2024
    Inventors: Colin South, Matthew Dunn, Lauren Fitch, Joseph Koos, Laura Holland, Brigid Arciero, James Spoonamore, Caitlin Allen, Alexander Hsu, Sara Tabandeh, Frederick Richard Kearney
  • Patent number: 11766463
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: September 26, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
  • Publication number: 20220362309
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 17, 2022
    Inventors: Kristin ADOLFSEN, Per GREISEN, Isolde CALLIHAN, Adam LAWRENCE, James SPOONAMORE, Jay KONIECZKA
  • Patent number: 10022357
    Abstract: The present disclosure relates to methods for treating a neurodegenerative disorder by administering an effective amount of an agent that inhibits or reduces translation of amyloid precursor protein. In some embodiments, the neurodegenerative disorder is Alzheimer's disease or Down syndrome. Also disclosed are methods for decreasing amyloid-beta production in a subject's brain. Further disclosed is a method for restoring or maintaining iron homeostasis in a subject's brain.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: July 17, 2018
    Assignees: THE GENERAL HOSPITAL CORPORATION, THE BROAD INSTITUTE, INC.
    Inventors: Jack T Rogers, Xudong Huang, James Spoonamore
  • Publication number: 20160074367
    Abstract: The present disclosure relates to methods for treating a neurodegenerative disorder by administering an effective amount of an agent that inhibits or reduces translation of amyloid precursor protein. In some embodiments, the neurodegenerative disorder is Alzheimer's disease or Down syndrome. Also disclosed are methods for decreasing amyloid-beta production in a subject's brain. Further disclosed is a method for restoring or maintaining iron homeostasis in a subject's brain.
    Type: Application
    Filed: April 29, 2014
    Publication date: March 17, 2016
    Inventors: Jack T. Rogers, Xudong Huang, James Spoonamore
  • Patent number: 7994168
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: August 9, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, James Spoonamore, Gregory Merriman, Joseph T Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang, Martin Smrcina
  • Patent number: 7750005
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: July 6, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Patent number: 7652007
    Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 26, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
  • Publication number: 20080221113
    Abstract: Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Application
    Filed: May 21, 2008
    Publication date: September 11, 2008
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Patent number: 7390814
    Abstract: Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: June 24, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Pavel Safar, James Spoonamore, Martin Smrcina
  • Publication number: 20070197539
    Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments
    Type: Application
    Filed: February 21, 2007
    Publication date: August 23, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, Martin Smrcina, James Spoonamore, Gregory Merriman, Joseph Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
  • Publication number: 20050085483
    Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Application
    Filed: February 13, 2004
    Publication date: April 21, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang